These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 32531869)

  • 1. Personalised biopsy schedules based on risk of Gleason upgrading for patients with low-risk prostate cancer on active surveillance.
    Tomer A; Nieboer D; Roobol MJ; Bjartell A; Steyerberg EW; Rizopoulos D;
    BJU Int; 2021 Jan; 127(1):96-107. PubMed ID: 32531869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Personalized Decision Making for Biopsies in Prostate Cancer Active Surveillance Programs.
    Tomer A; Rizopoulos D; Nieboer D; Drost FJ; Roobol MJ; Steyerberg EW
    Med Decis Making; 2019 Jul; 39(5):499-508. PubMed ID: 31319751
    [No Abstract]   [Full Text] [Related]  

  • 3. Predicting Biopsy Outcomes During Active Surveillance for Prostate Cancer: External Validation of the Canary Prostate Active Surveillance Study Risk Calculators in Five Large Active Surveillance Cohorts.
    Drost FH; Nieboer D; Morgan TM; Carroll PR; Roobol MJ;
    Eur Urol; 2019 Nov; 76(5):693-702. PubMed ID: 31451332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Compliance Rates with the Prostate Cancer Research International Active Surveillance (PRIAS) Protocol and Disease Reclassification in Noncompliers.
    Bokhorst LP; Alberts AR; Rannikko A; Valdagni R; Pickles T; Kakehi Y; Bangma CH; Roobol MJ;
    Eur Urol; 2015 Nov; 68(5):814-21. PubMed ID: 26138043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk-stratification based on magnetic resonance imaging and prostate-specific antigen density may reduce unnecessary follow-up biopsy procedures in men on active surveillance for low-risk prostate cancer.
    Alberts AR; Roobol MJ; Drost FH; van Leenders GJ; Bokhorst LP; Bangma CH; Schoots IG
    BJU Int; 2017 Oct; 120(4):511-519. PubMed ID: 28267899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Refined Analysis of Prostate-specific Antigen Kinetics to Predict Prostate Cancer Active Surveillance Outcomes.
    Cooperberg MR; Brooks JD; Faino AV; Newcomb LF; Kearns JT; Carroll PR; Dash A; Etzioni R; Fabrizio MD; Gleave ME; Morgan TM; Nelson PS; Thompson IM; Wagner AA; Lin DW; Zheng Y
    Eur Urol; 2018 Aug; 74(2):211-217. PubMed ID: 29433975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluating the Four Kallikrein Panel of the 4Kscore for Prediction of High-grade Prostate Cancer in Men in the Canary Prostate Active Surveillance Study.
    Lin DW; Newcomb LF; Brown MD; Sjoberg DD; Dong Y; Brooks JD; Carroll PR; Cooperberg M; Dash A; Ellis WJ; Fabrizio M; Gleave ME; Morgan TM; Nelson PS; Thompson IM; Wagner AA; Zheng Y;
    Eur Urol; 2017 Sep; 72(3):448-454. PubMed ID: 27889277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of outcomes of different biopsy schedules among men on active surveillance for prostate cancer: An analysis of the G.A.P.3 global consortium database.
    Beckmann KR; Bangma CH; Helleman J; Bjartell A; Carroll PR; Morgan T; Nieboer D; Santaolalla A; Trock BJ; Valdagni R; Roobol MJ;
    Prostate; 2022 May; 82(7):876-879. PubMed ID: 35254666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathological upgrading in prostate cancer patients eligible for active surveillance: Does prostate-specific antigen density matter?
    Jin BS; Kang SH; Kim DY; Oh HG; Kim CI; Moon GH; Kwon TG; Park JS
    Korean J Urol; 2015 Sep; 56(9):624-9. PubMed ID: 26366274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adherence to Active Surveillance Protocols for Low-risk Prostate Cancer: Results of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance Initiative.
    Kalapara AA; Verbeek JFM; Nieboer D; Fahey M; Gnanapragasam V; Van Hemelrijck M; Lee LS; Bangma CH; Steyerberg EW; Harkin T; Helleman J; Roobol MJ; Frydenberg M;
    Eur Urol Oncol; 2020 Feb; 3(1):80-91. PubMed ID: 31564531
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A biopsy-integrated algorithm for determining Gleason 6 upgrading risk stratifies risk of active surveillance failure in prostate cancer.
    Blute ML; Shiau JM; Truong M; Shi F; Abel EJ; Downs TM; Jarrard DF
    World J Urol; 2017 May; 35(5):729-735. PubMed ID: 27631325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative Analysis of Biopsy Upgrading in Four Prostate Cancer Active Surveillance Cohorts.
    Inoue LYT; Lin DW; Newcomb LF; Leonardson AS; Ankerst D; Gulati R; Carter HB; Trock BJ; Carroll PR; Cooperberg MR; Cowan JE; Klotz LH; Mamedov A; Penson DF; Etzioni R
    Ann Intern Med; 2018 Jan; 168(1):1-9. PubMed ID: 29181514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Decade of Active Surveillance in the PRIAS Study: An Update and Evaluation of the Criteria Used to Recommend a Switch to Active Treatment.
    Bokhorst LP; Valdagni R; Rannikko A; Kakehi Y; Pickles T; Bangma CH; Roobol MJ;
    Eur Urol; 2016 Dec; 70(6):954-960. PubMed ID: 27329565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate-specific antigen vs prostate-specific antigen density as a predictor of upgrading in men diagnosed with Gleason 6 prostate cancer by contemporary multicore prostate biopsy.
    Oh JJ; Hong SK; Lee JK; Lee BK; Lee S; Kwon OS; Byun SS; Lee SE
    BJU Int; 2012 Dec; 110(11 Pt B):E494-9. PubMed ID: 22540236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Magnetic Resonance Imaging-Guided Confirmatory Biopsy for Initiating Active Surveillance of Prostate Cancer.
    Jayadevan R; Felker ER; Kwan L; Barsa DE; Zhang H; Sisk AE; Delfin M; Marks LS
    JAMA Netw Open; 2019 Sep; 2(9):e1911019. PubMed ID: 31509206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nine-year Follow-up for a Study of Diffusion-weighted Magnetic Resonance Imaging in a Prospective Prostate Cancer Active Surveillance Cohort.
    Henderson DR; de Souza NM; Thomas K; Riches SF; Morgan VA; Sohaib SA; Dearnaley DP; Parker CC; van As NJ
    Eur Urol; 2016 Jun; 69(6):1028-33. PubMed ID: 26482887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of the Pathologic Gleason Score to Inform a Personalized Management Program for Prostate Cancer.
    Coley RY; Zeger SL; Mamawala M; Pienta KJ; Carter HB
    Eur Urol; 2017 Jul; 72(1):135-141. PubMed ID: 27523594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of biopsy under-sampling and annual progression using hidden markov models to learn from prostate cancer active surveillance studies.
    Li W; Denton BT; Nieboer D; Carroll PR; Roobol MJ; Morgan TM;
    Cancer Med; 2020 Dec; 9(24):9611-9619. PubMed ID: 33159431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors predicting prostate cancer upgrading on magnetic resonance imaging-targeted biopsy in an active surveillance population.
    Lai WS; Gordetsky JB; Thomas JV; Nix JW; Rais-Bahrami S
    Cancer; 2017 Jun; 123(11):1941-1948. PubMed ID: 28140460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of progression following a negative biopsy in prostate cancer active surveillance.
    Beckmann K; Santaolalla A; Sugimoto M; Carroll P; Rubio J; Villers A; Bjartell A; Morgan T; Dasgupta P; Van Hemelrijck M; Elhage O;
    Prostate Cancer Prostatic Dis; 2023 Jun; 26(2):403-409. PubMed ID: 36008540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.